FDA investigating cancer risk tied to CAR-T cell therapy

The agency said the benefit of approved treatments like Gilead’s Yescarta still outweighs any such risk, but the alert could slow drugmaker efforts to develop the treatments for wider use.

Click here to view original post

Advertisement — Advertise with Biotech Networks